Skip to content

The Efficacy of Oral Ginger Powder in Prevention of Postoperative Ileus after Benign Gynecologic Hysterectomy: A Randomized Controlled Trial

The Efficacy of Oral Ginger Powder in Prevention of Postoperative Ileus after Benign Gynecologic Hysterectomy: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20241117001
Enrollment
56
Registered
2024-11-17
Start date
2023-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To assess the efficacy of oral ginger powder for prevention of postoperative bowel ileus in benign gynecologic abdominal hysterectomy. ginger, benign gynecologic surgery, postoperative bowel ileus

Interventions

Post operation day 1 : receive ginger(500 mg) 2 capsules three time a day for 3 day ,Post operation day 1 : receive placebo 2 capsules three time a day for 3 day
Placebo Comparator Drug,Placebo Comparator Drug

Sponsors

Khon Kaen Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients included those diagnosed with benign gynecological conditions and scheduled for abdominal hysterectomy with or without adnexal surgery

Exclusion criteria

Exclusion criteria: had (a) a history of carminative drug use, (b) allergy to ginger, (c) reoperation within 24 hours, (d) immobility such as being on a ventilator, unconsciousness, or in shock, (e) intraoperative complications involving the gastrointestinal organs, kidneys, ureters or urinary bladder system, (f) underlying gastrointestinal disease such as gastroesophageal reflux disease and dyspepsia, (g) underlying chronic kidney disease (GFR < 30 ml/min/1.73m2), (h) use of anticoagulants such as warfarin, (i) postoperative flatus before the start of the intervention, (j) underlying respiratory disease such as COPD, asthma, or lung cancer, (k) peripheral arterial occlusion disease, (l) an operative time > 3 hours, (m) a low albumin level (< 3.5 g/dL), or (n) intraabdominal infection

Design outcomes

Primary

MeasureTime frame
Time to first flatus until discharge mean

Secondary

MeasureTime frame
Time to first defecation until discharge mean,Time to first defecation Time to first defecation mean,postoperative vomiting post operative day1-3 number,Adverse events until discharge number,Additional antiflatulent or laxative drug requirements until discharge number

Countries

Thailand

Contacts

Public Contactwitchuda Lorsirirat

khonkaen hospital

kookkaii.kk28@gmail.com0918678975

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026